Resource table {#s0005}
==============

Name of stem cell lineKCL013InstitutionKing\'s College London, London, UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: <dusko.ilic@kcl.ac.uk>Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature (direct URL links and full references)1)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122--128.doi: 10.3109/14653249.2011.623692\
<http://www.ncbi.nlm.nih.gov/pubmed/22029654>\
2)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366--1381.doi: 10.1038/nprot.2012.080\
<http://www.ncbi.nlm.nih.gov/pubmed/22722371>Information in public databasesKCL013 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: 0214\
NIH Approval Number: NIHhESC-13-0214\
<http://grants.nih.gov/stem_cells/registry/current.htm?id=651>EthicsThe hESC line KCL013 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

Resource details {#s0010}
================

Consent signedAug 12, 2009Embryo usedAug 23, 2009UK Stem Cell Bank\
Deposit approvalSep 23, 2010\
Reference: SCSC10-32SexMale 46, XYGradeResearchDisease status\
([Fig. 1](#f0005){ref-type="fig"})Mutation affecting one allele of the *HTT* gene encoding huntingtin (\~ 46 CAG repeats; 17 for the normal allele) associated with Huntington\'s disease ([@bb0015])Karyotype (G banding)\
([Fig. 2](#f0010){ref-type="fig"})No imbalance detectedKaryotype (aCGH)No imbalance detectedDNA fingerprintAllele sizes (in bp) of 17 microsatellite markers specific for chromosomes 13, 18 and 21 ([@bb0015])Viability testingPassPluripotent markers\
(immunostaining)\
([Fig. 3](#f0015){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity ([@bb0015])Three germ layer differentiation in vitro (immunostaining)\
([Fig. 4](#f0020){ref-type="fig"})Endoderm: AFP (α-fetoprotein); ectoderm: TUBB3 (tubulin, β3 class III); mesoderm: ACTA2 (actin, α2, smooth muscle) ([@bb0015])Sibling lines availableKCL012

We generated KCL013 clinical grade hESC line following protocols, established previously ([@bb0015], [@bb0025]). The expression of the pluripotency markers was tested after freeze/thaw cycle ([Fig. 3](#f0015){ref-type="fig"}; [@bb0015]). Differentiation potential into three germ layers was verified in vitro ([Fig. 4](#f0020){ref-type="fig"}; [@bb0015]).

Materials and methods {#s0015}
=====================

Consenting process {#s0020}
------------------

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent form were mailed to them. If in the meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (PGD-V.6) were created on Aug. 10, 2007. HFEA Code of Practice that was in effect at the time of document creation: Edition 7 --- R.1 (<http://www.hfea.gov.uk/2999.html>). The donor couple signed the consent on Oct. 15, 2009. HFEA Code of Practice that was in effect at the time of donor signature: Edition 8 --- R.1. HFEA Code of Practice Edition 7 --- R.1 was in effect until Dec. 09, 2007 and Edition 8 --- R.1 was in effect: Oct. 01, 2009--Apr. 06, 2010.

Embryo culture and micromanipulation {#s0025}
------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details ([@bb0015], [@bb0025]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

Cell culture {#s0030}
------------

ICM plated on mitotically inactivated HFF was cultured as described ([@bb0015], [@bb0025]). Trophectoderm cells were removed mechanically from outgrowth ([@bb0005], [@bb0010]). hESC colonies were expanded and cryopreserved at the third passage.

Viability test {#s0035}
--------------

Straws with the earliest frozen passage (p. 2--3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

Pluripotency markers {#s0040}
--------------------

Pluripotency was assessed using two different techniques: enzymatic activity assay \[alkaline phosphatase (AP) assay\] and immunostaining as described ([@bb0015], [@bb0025]).

Genotyping {#s0045}
----------

DNA was extracted from hESC cultures using a Chemagen DNA extraction robot according to the manufacturer\'s instructions. Amplification of polymorphic microsatellite markers was carried out as described ([@bb0015]). Allele sizes were recorded to give a unique fingerprint of each cell line.

Differentiation {#s0050}
---------------

Spontaneous differentiation into three germ layers was assessed in vitro and in vivo as described ([@bb0020], [@bb0025]).

Array comparative genomic hybridization (aCGH) {#s0055}
----------------------------------------------

aCGH was performed as described in detail ([@bb0015]).
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![Genetic pedigree tree. The couple undergoing IVF had 12 embryos in this particular cycle. Three embryos were normal, whereas nine carried the mutation in *HTT* and were donated for research. We derived hESC lines from two of them.](gr1){#f0005}

![A modal karyotype (in 19 cells) showed a normal male chromosome complement and banding pattern. In addition, one anomalous cellwas seen (45,XY,− 19), believed to be the result of harvesting artifact.](gr2){#f0010}

![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (OCT4, NANOG, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar, 50 μm.](gr3){#f0015}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 100 μm.](gr4){#f0020}
